Treats overactive bladder with symptoms of urge urinary incontinence, urgency and…. ANDA 206743, held by Aurobindo Pharma. Darifenacin Hydrobromide.
As of Nov 16, 2026, ANDA 206743 (Darifenacin Hydrobromide), held by Aurobindo Pharma, was first approved by FDA on Sep 19, 2016, with 0 approved supplements and 0 published complete response letters.
Darifenacin extended-release tablets are indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and frequency.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 19, 2016 | Original application | Approved | None posted |
| Darifenacin HydrobromideEQ 7.5MG BASE · tablet, extended release;oral | Darifenacin Hydrobromide | Rx |
| Darifenacin HydrobromideEQ 15MG BASE · tablet, extended release;oral | Darifenacin Hydrobromide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters